We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+6.8%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.57B
AUM Growth
+$1.06B
Cap. Flow
+$745M
Cap. Flow %
7.79%
Top 10 Hldgs %
36.3%
Holding
159
New
27
Increased
34
Reduced
20
Closed
32

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$202M
2
COO icon
Cooper Companies
COO
+$180M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$78.3M
4
SHPG
Shire pic
SHPG
+$77.9M
5
WMGI
Wright Medical Group Inc
WMGI
+$75.3M

Top Sells

Rank Stock Value
1
ITMN
INTERMUNE INC
ITMN
+$240M
2
VTRS icon
Viatris
VTRS
+$184M
3
AGN
Allergan Inc
AGN
+$107M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$89.3M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$43.7M

Sector Composition

Rank Sector Weight
1 Healthcare 83.95%
2 Financials 0.07%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QGENF
51
DELISTED
QIAGEN NV
QGENF
$38.7M 0.4%
1,700,000
+918,600
+118% +$20.9M
AFMD
52
DELISTED
Affimed
AFMD
$36.6M 0.38%
+581,463
New +$36.3M
TEVA icon
53
Teva Pharmaceuticals
TEVA
$40B
$35.6M 0.37%
+662,000
New +$35.1M
EXAS
54
DELISTED
Exact Sciences
EXAS
$33.4M 0.35%
1,723,000
– –
ROKA
55
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$32.4M 0.34%
+322,043
New +$35M
SLXP
56
CALL
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$31.2M 0.33%
+200,000
New +$29M
COO icon
57
CALL
Cooper Companies
COO
$14.2B
$31.1M 0.33%
+800,000
New +$31.5M
XNPT
58
DELISTED
XENOPORT, INC.
XNPT
$29.8M 0.31%
5,546,100
– –
CERS icon
59
Cerus
CERS
$585M
$28.8M 0.3%
7,185,000
+2,947,000
+70% +$11.3M
LOXO
60
DELISTED
Loxo Oncology, Inc
LOXO
$28.6M 0.3%
+2,175,857
New +$28.2M
INSY
61
DELISTED
Insys Therapeutics, Inc.
INSY
$28.5M 0.3%
+1,471,200
New +$23.1M
CLDX icon
62
Celldex Therapeutics
CLDX
$2.82B
$28.3M 0.3%
145,440
– –
AMGN icon
63
CALL
Amgen
AMGN
$213B
$28.1M 0.29%
+200,000
New +$26.1M
MNK
64
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$26.5M 0.28%
+294,001
New +$23M
MDT icon
65
Medtronic
MDT
$112B
$26.2M 0.27%
423,300
– –
NUVA
66
DELISTED
NuVasive, Inc.
NUVA
$23.1M 0.24%
662,000
+346,000
+109% +$12.3M
PCRX icon
67
Pacira BioSciences
PCRX
$1.05B
$23.1M 0.24%
+237,900
New +$23.1M
AMBI
68
DELISTED
Ambit Biosciences Corp
AMBI
$23M 0.24%
1,490,769
– –
ARRY
69
DELISTED
Array Biopharma Inc
ARRY
$22.9M 0.24%
6,402,800
– –
DRTX
70
DELISTED
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
$22.6M 0.24%
1,785,714
– –
MGLN
71
DELISTED
Magellan Health Services, Inc.
MGLN
$22M 0.23%
+402,600
New +$23.1M
COV
72
CALL
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
$21.6M 0.23%
+250,000
New +$22.1M
PTLA
73
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$21.5M 0.22%
850,700
-510,900
-38% -$13.5M
CAH icon
74
Cardinal Health
CAH
$54.3B
$20.8M 0.22%
277,000
– –
MRTX
75
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$20.4M 0.21%
1,167,000
-5,000
-0.4% -$93.3K
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2014 Portfolio in Review

As of Q3 2014, OrbiMed held 159 positions worth $9.57B, up 12% from $8.52B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

OrbiMed deployed $745M of net new capital in Q3 2014, opening 27 new positions and adding to 34 existing holdings. Its largest new stake was Cooper Companies: 4,570,800 shares worth $178M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 83% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Viatris, an estimated $184M trimmed.

  • OrbiMed's largest Q3 2014 buy was Cooper Companies: 4,570,800 shares worth $178M.
  • OrbiMed added most to Allergan plc in Q3 2014, an estimated $202M increase.
  • OrbiMed's biggest Q3 2014 reduction was Viatris, cutting an estimated $184M.
  • OrbiMed fully exited INTERMUNE INC in Q3 2014, selling an estimated $240M.
  • OrbiMed's ten largest holdings make up 36% of its $9.57B portfolio in Q3 2014.
  • OrbiMed opened 27 new positions and closed 32 in Q3 2014.
  • OrbiMed's portfolio value rose 12% quarter-over-quarter to $9.57B.

Based on OrbiMed's 13F filing for Q3 2014, filed 14 Nov 2014.